CAR-Ts redirected against the Thomsen-Friedenreich antigen CD176 mediate specific elimination of malignant cells from leukemia and solid tumors

CAR-Ts redirected against the Thomsen-Friedenreich antigen CD176 mediate specific elimination of malignant cells from leukemia and solid tumors

IntroductionChimeric antigen receptor-engineered T cells (CAR-Ts) are investigated in various clinical trials for the treatment of cancer entities beyond hematologic malignancies. A major hurdle is the identification of a target antigen with high expression on the tumor but no expression on healthy...

Full description

Bibliographic Details
Main Authors: Anna Christina Dragon, Luca Marie Beermann, Melina Umland, Agnes Bonifacius, Chiara Malinconico, Louisa Ruhl, Patrik Kehler, Johanna Gellert, Lisa Weiß, Sarah Mayer-Hain, Katharina Zimmermann, Sebastian Riese, Felicitas Thol, Gernot Beutel, Britta Maecker-Kolhoff, Fumiichiro Yamamoto, Rainer Blasczyk, Axel Schambach, Michael Hust, Michael Hudecek, Britta Eiz-Vesper
Format: Article
Language:English
Published: Frontiers Media S.A. 2023-10-01
Series:Frontiers in Immunology
Subjects:
CD176
Thomsen-Friedenreich antigen
pan-tumor antigen
carbohydrate antigen
CAR-T cell therapy
immunotherapy
Online Access:https://www.frontiersin.org/articles/10.3389/fimmu.2023.1219165/full

Internet

https://www.frontiersin.org/articles/10.3389/fimmu.2023.1219165/full

Similar Items